Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07482384 · ClinicalTrials.gov registry record · NA
Supporting Health Including Endocrine Treatment for Long Duration
A NA study, sponsored by Dana-Farber Cancer Institute.
- Not yet
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT07482384: Clinical Trial NA study, sponsored by Dana-Farber Cancer Institute.
NCT07482384 is a NA study that has not yet begun recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07482384, a NA study, has not yet begun recruiting, sponsored by Dana-Farber Cancer Institute.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
This research is being done to pilot an intervention which aims to test a new web- and mobile application ("app")-based supportive care tool (SHIELD portal) and to assess the feasibility of enrolling female breast cancer patients with hormone receptor-positive disease long-term endocrine treatment.
Primary Outcome
Enrollment yield is defined as the proportion of participants approached for the study intervention (SHIELD, Supporting Health Including Endocrine Treatment for Long Duration) who enroll.
Interventions
- BEHAVIORAL SHIELD portal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-05 |
| Est. Completion | 2027-05 |
| Phase | NA |
What is known before NCT07482384 opens enrollment
NCT07482384 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which SHIELD portal is the first listed.
NCT07482384 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07482384 about?
NCT07482384 is a clinical study titled "Supporting Health Including Endocrine Treatment for Long Duration". This research is being done to pilot an intervention which aims to test a new web- and mobile application ("app")-based supportive care tool (SHIELD portal) and to assess the feasibility of enrolling female breast cancer patients with hormone receptor-positive disease long-term endocrine treatment.
What is the current status of trial NCT07482384?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2026-05. Estimated completion is 2027-05.
What interventions are being tested in trial NCT07482384?
The interventions under investigation include: SHIELD portal (BEHAVIORAL).
Who is sponsoring clinical trial NCT07482384?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07482384's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia